Academician Mao Zhenbin and his delegation from the China Food and Drug Corporation Quality and Safety Promotion Association visited Leadingpharm to jointly explore a new chapter of high-quality development in the industry

In order to promote the development of the food and drug industry towards higher quality, assist in the comprehensive improvement of the national food and drug safety strategy and technological innovation, Academician Mao Zhenbin, President of the China Food and Drug Corporation Quality and Safety Promotion Association(FDSA),and Mr. Huang Xinwang, vice President of FDSA, and the delegation recently visited the Beijing Research Institute of Leadingpharm (Vice President Unit of FDSA), and had an in-depth and effective exchange and cooperation with the leadership team of Leadingpharm.
 

In order to promote the development of the food and drug industry towards higher quality, assist in the comprehensive improvement of the national food and drug safety strategy and technological innovation, Academician Mao Zhenbin, President of the China Food and Drug Corporation Quality and Safety Promotion Association(FDSA),and Mr. Huang Xinwang, vice President of FDSA, and the delegation recently visited the Beijing Research Institute of Leadingpharm (Vice President Unit of FDSA), and had an in-depth and effective exchange and cooperation with the leadership team of Leadingpharm.
 

Both sides agree that regulatory science is the key to enhancing drug regulatory capacity and governance level, and it is also an important support for China to be a pharmaceutical powerhouse. In the current era of pharmaceutical innovation, attention should be paid to the application and integration of regulatory science in real-world research and innovative drug development, which can more accurately evaluate the effectiveness and safety of drugs in clinical practice, and provide more comprehensive and authentic data support for policy makers, clinical institutions and pharmaceutical R&D enterprises.
 

During the meeting, both sides also exchanged ideas on the construction and development of innovative pharmaceutical brands. Leadingpharm has demonstrated outstanding R&D capabilities and profound industry experience in the entire CXO industry chain, always guided by regulatory science. Based on top-level design of scientific regulation, it is committed to providing innovative pharmaceutical enterprises with comprehensive and full lifecycle innovation services, from technology research and development to product registration, smooth transformation from IND to NDA, and maximization of product commercial value, helping enterprises to develop rapidly and continuously innovate in the pharmaceutical field. The China Food and Drug Enterprise Quality and Safety Promotion Association, as an important force in promoting industry development, actively builds platforms to promote deep integration of industry, academia, research and application. Both sides stated that they will rely on the platform of FDSA and combine the advantages of the entire industry chain of Leadingpharm to jointly build a drug innovation service committee with regulatory science as the main line, play a positive role in providing consultation to the government, serving enterprise development, optimizing resource allocation, strengthening industry self-discipline, innovating social governance, fulfilling social responsibilities, and other aspects.
 

In the field of real-world research, the cooperation between the two sides also shows a trend of deep integration. The research and application of real-world data provide more realistic and accurate data support for drug development and transformation, which helps to improve the quality and efficiency of drug development. Leadingpharm has rich experience and resources in this field, and will work together with FDSA to explore the application mode of real-world data in drug research and development transformation, promoting the speed of innovative drug research and marketing. Both parties will also jointly develop research standards, improve data collection and analysis methods, and enhance the scientific and practical nature of the research.
 

This visit and exchange not only demonstrate the joint responsibility of associations and enterprises in promoting high-quality development of the industry, but also indicate that China's food and drug industry will take more solid steps on the path of regulatory science and innovative development. In the future, both sides will continue to deepen cooperation and jointly contribute wisdom and strength to the prosperity and development of China's pharmaceutical industry.